Mesothelioma

Dr. Perez-Soler News

Agennix Receives Special Protocol Assessment Approval From FDA For The Pivotal Trial Of Talactoferrin Alfa In ...Friday, January 18, 2008 @ 4:05AMAgennix Incorporated announced that the U.S. Food and Drug Administration (FDA) has approved the design of a single, pivotal, Phase 3 trial evaluating its lead molecule, talactoferrin alfa, in combination with chemotherapy as first-line treatment in patients with non-small cell lung cancer (NSCLC) under the Special Protocol Assessment (SPA) process.

Agennix Receives Special Protocol Assessment Approval from FDA for the Pivotal Trial of Talactoferrin Alfa in ...Thursday, January 17, 2008 @ 7:00AM Agennix Incorporated announced today that the U.S. Food and Drug Administration has approved the design of a single, pivotal, Phase 3 trial evaluating its lead molecule, talactoferrin alfa, in combination with chemotherapy as first-line treatment in patients with non-small cell lung cancer under the Special Protocol Assessment process.